Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.
about
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus InfectionRecognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic reviewAntiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaColonic mucosa-associated lymphoid tissue lymphoma identified by chromoendoscopy.HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions.Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.Pediatric nodal marginal zone lymphoma may develop in the adult population.Early, Isolated Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma Presenting without Symptoms or Grossly Apparent Endoscopic Lesions and Diagnosed by Random Duodenal Biopsies.Epidemiology, pathology and treatment of non-follicular indolent lymphomas.Nodal marginal zone lymphoma.Non-Hodgkin lymphoma and hepatitis C: where we are and what next?Quadri-lineage disease involving nodal B-cell marginal zone lymphoma, high-grade B-cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia.Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma.Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma.Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
P2860
Q26775733-7D3F5C9E-7434-4A9A-84E4-2984353B6F6BQ26996650-EE569EC6-9894-4EB0-B644-C4ABF7E14E5BQ28080160-A801B081-E8D6-4093-A331-4386B77D90D2Q34779318-519BBEC5-3328-4FBD-A746-FB5CD88119F7Q35854495-C0094C38-BBB1-4897-AF02-576672B04C1AQ36204525-64D66B3B-7882-4FC6-BDEC-CA39E7777838Q36610861-8063C1DB-4A99-4C77-B425-32E02FF5CDC4Q37096322-76DD179F-9D81-4A28-B869-1DEC6E5C1381Q37280928-FDE57E8D-520A-45ED-AADF-B28B90AE3AA4Q38134139-E8C7C0FF-D386-44C2-9F55-9727342E47A6Q38255923-3ED4D7A2-14C5-4024-ADE4-2F3760777EE2Q42881730-CE951404-E320-4E52-A37F-314123020C20Q43047628-7B210F93-1FA3-40AC-9B61-7FBC4D13188BQ44223923-3500B892-B738-4905-BB08-77F6E0C741A8Q45756830-DCE1068B-B524-46DC-851F-6C8D59C8C74CQ47449201-959573CD-73AB-4979-9AFE-BB7777DE31DFQ51626445-8D55F291-7A2F-4193-A255-78F56FC7B6E1Q51626523-73EECB77-86B5-4DB9-A875-8E3B815E5080Q52599792-FE16A635-A01D-49EE-8223-4B868CBDF9F5Q53208977-4F1110EE-0241-47A3-B3D2-86732C15B098Q57759549-866DC1DD-9B6A-49EE-A3B3-398EF7B28C87
P2860
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Primary nodal marginal zone B- ...... assessment of a rare disease.
@en
Primary nodal marginal zone B- ...... assessment of a rare disease.
@nl
type
label
Primary nodal marginal zone B- ...... assessment of a rare disease.
@en
Primary nodal marginal zone B- ...... assessment of a rare disease.
@nl
prefLabel
Primary nodal marginal zone B- ...... assessment of a rare disease.
@en
Primary nodal marginal zone B- ...... assessment of a rare disease.
@nl
P2093
P2860
P50
P1476
Primary nodal marginal zone B- ...... c assessment of a rare disease
@en
P2093
Andrea Gallamini
Andrea Rossi
Antonio Ramponi
Cristiana Pascutto
Emanuela Bonoldi
Enrica Morra
Francesca Montanari
Intergruppo Italiano Linfomi
Lilj Uziel
Marco Lucioni
P2860
P304
P356
10.1111/J.1365-2141.2006.06437.X
P407
P577
2007-01-01T00:00:00Z